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Introduction 
 Gliomas are the most common primary 
tumors which arise from cells of the brain 
itself rather than metastazing to the brain from 
another location in the body. It can be slow 
growing (low grade, grades 1 and 2) or rapidly 
growing (high grade, grades 3 and 4). For 
instance, diffuse and fibrillary astrocytomas 
are divided histopathologically into three 
grades of malignancy: World Health 
Organization (WHO) grade II astrocytomas, 
WHO grade III anaplastic astrocytoma and 
WHO grade IV glioblastoma multiforme 
(GBM) (Otto, 2001). 
 It seem to have the genomic alterations at 
the chromosome level somewhere in DNA 
that are characteristic of each type of tumor 
and most stages of progression but not much 
is known. Because of this factor, it present a 
major therapeutic challenge, there is a strong 
rationale for examining the efficacy of novel 
chemotherapeutic strategies as a means for 
enhancing disease control (Devaux et al., 
1993).  
 An understanding of these specific genetic 
alterations will give information to the 
oncologists in doing cancer therapy, which is 
currently based only on cancer classification 
such as for gliomas, one of the major groups 
in brain tumor. 
 Thus, the aim of this study were to 
determine the EC50 value for bis[S-methyl- -
N-(2-furylmethylketone)dithiocarbazato] 
cadmium (II) (SMDB-Cd) in order to screen 
the cytotoxic effects on human gliomas cell 
lines then to examine and compare the 
deletion and amplification patterns in whole 
chromosomes in normal DNA (reference) and 
DNA from gliomas cell lines (test) before and 
after treatment with SMDB-Cd using CGH 
and to confirm that p53 gene is one of the 
genes involved in progression of the gliomas 
by using p53 FISH probe. 
 
Materials and methods 
 
Cell lines and culture medium 
Three different stages of human glioma 
cell lines were used; A172 (glioblastoma), 
U87 MG (astrocytoma grade III) and T98G 
(glioblastoma multiforme) were all purchased 
from American Type Culture Collection 
(ATCC), USA. A172 was cultured in DMEM 
and U87MG and T98G in EMEM. All media 
was supplemented with 10% Fetal Bovine 
Serum (FBS), 100U/ml and 100mg/ml 
Penicillin-Streptomycin solution and 2mM L-
Glutamine (4mM L-glutamine).  
 
Compound preparation 
 The SMDB-Cd compound was dissolved in 
0.05% dimethyl sulfoxide (DMSO, pH 4.7) 
(Amresco, USA) and diluted with DMEM 5% 
FBS and EMEM 5% FBS for treatment on 
U87MG, A172 and T98G. Tamoxifen 
(SIGMA, USA) a commercially available 
drug which is used very common to treat brain 
cancer was used as the control and was 
prepared by using the same method. 
 
In vitro cytotoxicity assay 
 Investigation on the effects of SMDB-Cd on 
cell growth inhibition employed the use of 
MTT assay. Cells (1 X 105 cells/well for 
HCN-2, A172, U87MG and T98G cells) were 
plated with nutritional medium (DMEM 5% 
FBS or EMEM 5% FBS) in 96 well plates. 
The total volume for each well was 100µl. 
After 24 hours, cells were treated with 
different concentrations of SMDB-Cd and 
tamoxifen (control) for 72 hours. The plates 
contain 100 microliters (µl) of media in each 
96 well with addition of the compound and 
media to a total volume of 200 microliters. 
After treatment for 72 hours, twenty 
microliters of MTT (Sigma, USA) solution [5 
mg/ml in 1X PBS] was added to each well and 
then wrapped with aluminium foil. The plates 
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were then reincubated at 37°C in 5% CO2. 
After 4 hours of incubation, the medium was 
discarded and 200 µl of lysis buffer, DMSO 
(pH 4.7) (Amresco, USA), was added to each 
well, followed by 15 minutes incubation at 
37°C in 5% CO2 to dissolve the reduced MTT 
crystal. The absorbance of the samples was 
then measured by an ELISA reader 
(DynexMRX II) at 530nm. Each of the 
experiment was repeated at least 3 times.  The 
EC50 values were then analyzed using T-test to 
test for the significance and data were given as 
mean + standard error means (SEM).  
 
Comparative genomic hybridization (CGH) 
High-quality metaphases chromosome 
spreads from a karyotypically normal male for 
CGH were commercially bought (Vysis). 
Briefly, DNA from untreated and treated cell 
lines with SMDB-Cd and peripheral blood 
cells was extracted using a Dneasy™ Tissue 
kit (Qiagen) and QIAamp Blood Mini kit 
(Qiagen). Tumor and reference DNA were 
labeled with SpectrumGreen-dUTP and 
SpectrumRed-dUTP (Vysis) respectively, 
using a nick translation kit (Vysis). Both DNA 
were simultaneously hybridized for 16-24 
hours at 37°C in HYBrite™ system 
(Interscience, Germany). Chromosome 
counterstaining was achieved by using 
DAPI/antifade (Vysis). 
 
Fluorescence in situ hybridization (FISH)      
 Fish study was performed on those cell lines in 
order to confirm the CGH findings. Metaphases 
chromosome spreads were prepared from 
untreated and treated cell lines and peripheral 
blood cells according to standard protocols. 
FISH was carried out using a unique sequence 
probe for the p53 gene (Vysis). The 
experiments were performed according to the 
protocols supplied by probe’s manufacturer. 
 
Digital image analysis 
 CGH and FISH results were analyzed 
using Leica fluorescence microscope (Leica 
System, Germany) equipped with appropriate 
filters. Between 10 and 15 mwtaphases were 
chosen for image analysis based on their high 
fluorescence intensity and uniform 
hybridization. Gray-level images were 
captured separately for each fluorochrome 
(DAPI, SpectrumGreen and SpectrumRed). 
Karyotyping was performed based on DAPI 
banding and was achieved by inverting the 
DAPI image. For CGH, green-to- red 
fluorescence intensity ratio profiles were 
calculated after background correction and 
normalization of the green-to-red ratio for 
each metaphase to 1.0. Mean ratio profiles for 
each chromosome were determined after data 
from all analyzed metaphases were combined. 
Ratio values that were under 0.8 and over 1.2 
corresponded respectively to loss and gain of 
DNA sequences in the DNA study.  In FISH 
analysis, only yellow and blue images were 
collected.   
  
Results 
 
Cytotoxic activity of the SMDB-Cd on 
human glioma cell lines 
The cytotoxic activity of the SMDB-Cd 
was found the most effective on the U87MG 
cell line, followed by T98G, then A172 and 
lastly HCN-2. These MTT results demonstrate 
that the U87MG cell line was more sensitive 
to the SMDB-Cd compared to the others cell 
lines. EC50 of tamoxifen on A172, U87MG 
and HCN-2 were 7µl/ml and 5µl/ml 6µl/ml 
respectively (Table 1) which is comparable to 
that reported in the literature for U87MG was 
at 5.57 µg/ml (Brondani et al, 1999). Figure 1 
shows the cell viability for each cell line 
treated with Tamoxifen concentrations for the 
control.  Meanwhile Figure 2 shows the cell 
viability for each cell line treated with SMDB-
Cd. Graph line for each figure representing 72 
hour treatment. Therefore, SMDB-cd is more 
potent than tamoxifen. 
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TABLE 1 EC50 of the synthetic compound, 
SMDB-Cd compared to tamoxifen on HCN-2, 
A172, U87MG and T98G cell lines. 
 
 
FIGURE 1 Cytotoxicity effect of tamoxifen on 
glioma cell lines A172, T98G and U87MG. 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 2: Cytotoxicity effects of SMDB-Cd on 
glioma cell lines 
 
CGH  
 In untreated cell lines, the most frequently 
observed alteration involved gains of 7p and 
12q which were detected in all the cell lines. 
Losses of 9p, 10, 17p and 19q were only 
observed in A172 and U87MG. In T98G, the 
losses region only involved chromosome 9p 
and 10 (Figure 3). After treatment with the 
SMDB-Cd, there are two group of observation 
is done in the cell lines. Attention is given to 
the regions that show still remains which 
means not affected by the compound or no 
changes observed in each cell line and the 
regions that may affected by the compound 
(Figure 4). 
 
 
 
 
 
 
FIGURE 3 The average green to red fluorescence 
ratio profiles of each cell line before treatment 
with the SMDB-Cd computed from the 10 ratio 
images. 
 
 
 
 
 
 
 
 
FIGURE 4 Summary of genetic imbalances 
detected by CGH in each cell line after treatment 
with SMDB-Cd. 
 
 
FISH 
FISH analysis found significance deletion 
of p53 in untreated A172 and U87MG cell 
lines. Its means there were abnormalities in 
p53 involved in those gliomas cell line that 
agreed with the CGH results. In T98G, two 
copy of p53 gene was the most frequent 
observed. However, examination of the p53 
level in treated cell lines showed the 
increasing of p53 signal appeared in T98G. 
Two copies of p53 signals in a normal cell are 
presented in figure 5a. Figures 5b, 5c, 5d and 
5e show the examples of p53 signal in 
untreated and treated cell lines.  
 
 
 
 
 
 
 
Cell lines 
 
Tamoxifen 
 
SMDB-Cd 
 
HCN-2 
 
6 µg/ml ±0.10 
 
 
1.5 µg/ml 0.145 
 
 
A172 
 
7 µg/ml ±0.15 
 
 
0.7 µg/ml ±0.02 
 
 
U87MG 
 
5 µg/ml ±0.09 
 
 
0.3 µg/ml±0.006 
 
 
T98G 
 
4 µg/ml ±0.44 
 
 
0.4 µg/ml ±0.028 
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                 5a                                 
                      
5b                               5c 
   
5d         5e 
    
FIGURE 5 Results of FISH experiments using 
Vysis LSI p53 (17p13.1) probe (yellow) performed 
on chromosome preparations of samples (red 
arrows). 5a) Normal peripheral blood lymphocytes 
cells with two copies of the p53 gene. 5b) 
Untreated A172 and U87MG with one copy of the 
p53 gene. 5c) Treated A172 and U87MG with one 
copy of the p53 gene. 5d) Untreated T98G with 
two copies of the p53 gene. 5e) Multiples signal of 
p53 gene in each T98G cell after treatment with 
SMDB-Cd (red arrow) (100X magnification). 
 
Discussion 
Results of the present study revealed that 
the SMDB-Cd appeared to be more active and 
also showed more potent activity (in terms of 
EC50) as compared to tamoxifen, indicating 
that this compound could be a possible 
candidate against glioma. A compound is 
indicative of weak cytotoxic activities when 
the EC50 values are more than 10 – 25 µg/ml 
(Shier, 1991). A compound is 
chemotherapeutically significant and actively 
cytotoxic when the EC50 < 4 µg/ml (Geran et 
al., 1972 and Shier, 1991). The EC50 value of 
the SMDB-cd is in nanogram concentrations, 
which is well below 4 µg indicating the 
compound is chemotherapeutically 
significantly (Geran et al; 1972; Shier, 1991).   
The CGH with spectrum-green labeled 
tumors cell lines DNA and normal spectrum-
red labeled reference DNA revealed frequent 
gains of DNA at 7p and 12q, and losses of 
chromosome 9p, 10, 17p and 19q indicating 
that these regions contain candidate tumor 
suppressor genes involved in gliomas. These 
results are concordant with previously 
reported genomic aberrations in gliomas (Liau 
et al., 2001). Accordingly, all these regions 
may be significant in the development or 
progression of gliomas, and the cell lines 
examined are likely to be useful resources for 
genetic analysis. Recent work of focusing on 
the gains and losses of these regions has been 
shown to play a critical role in the 
oncogenesis of malignant tumors (Liau et al., 
2001).  
 The expected high green to red ratio at the 
regions above that corresponds to the some 
genes such as: EGFR, MDM2, p53 and PTEN, 
loci are clear in all cell lines. The height of the 
peak does not quantitatively reflect the level 
of amplification because the fluorescent signal 
spreads over a region of the chromosome that 
is larger than the length of the amplicon 
(Kallionemi et al., 1992). This is apparently a 
result of the target DNA in the denatured 
chromosomes. The CGH technique provides a 
means to detect and map such sequences. 
Several amplified loci were mapped and many 
at regions of the genome where amplification 
had not been suspected. Thus, a large variety 
of genes may be amplified during cancer 
initiation and progression (Kallioniemi et al., 
1992). 
 The region of 7p12-14 was the most 
common region showing DNA copy number 
gain in all cell lines. Liau et al. (2001) stated 
that an increased copy number at 7p12-14 is 
the aberration occurring most frequently in 
gliomas. This region contains the EGFR gene 
for a 170 kDa protein. EGFR is a 
transmembrane tyrosine kinase receptor that 
binds to at least two ligands: EGF and TGF-α. 
Careful study of EGFR 
overexpression/amplification and p53 
mutations has demonstrated that primary 
glioblastomas are associated with EGFR 
overexpression/amplification, but that p53 
mutations are rare in this subgroup.  This is in 
agreement with this study where a gain of 
7p12-14 is clearly shown in all 10 metaphase 
for each cell line but the deletion of p53 was 
only shown in U87MG and A172 (by CGH). 
These results suggest that T98G may not arise 
from the lower grade astrocytomas and 
U87MG and A172 may arise through 
progression from lower grade astrocytomas.  
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  In this study, aberrations of the p53 gene 
on chromosome 17 were observed in all three 
cell lines.  In A172 and U87MG, none or only 
one copy of the p53 gene was detected before 
treatment compared to the normal control that 
have two copies of the p53. This finding 
implies that both of these cell lines were found 
to have deletion on one or both copies of p53 
gene. However, in T98G, some interphase 
cells show both copies of the p53 signal that 
means this cell line has a wild type copy of 
p53. After treatment with SMDB-Cd, the p53 
signal was shown to have more than two 
signals in T98G. This amplification of p53 
which appears in the treated T98G may be due 
to the action of the cadmium complex, 
SMDB-Cd on the inhibition of cell growth 
and lead to DNA damage. SMDB-Cd may 
have inhibited division of cells that lead to the 
accumulation of p53 gene in a cell (figure 5e).  
This finding is in agreement with a 
previous report which showed that non-
repaired drug-induced DNA damage may 
result in: i) inhibition of DNA synthesis, ii) 
alteration in gene expression, iii) induction of 
apoptosis and iv) loss of genetic information. 
Generally, it has been assumed that DNA 
lesions block DNA synthesis and prevent 
cellular replication. Even if the lesion can be 
by-passed, persistence of the lesion in one cell 
and possible loss of genetic information in 
both daughter cells may eventually be lethal. 
DNA lesions may also have pronounced 
effects on gene expression, affecting RNA 
elongation or even the binding of polymerases 
and transcription factors (Yarnold et al., 
1993).  
Differential tolerance of DNA damage 
could account for differences in sensitivity to 
a chemotherapeutic drug, either between 
normal and neoplastic cells, or between 
sensitive and resistant tumors. Many features 
of cell death induced by anticancer drugs, 
such as chromatin condensation and activation 
of DNA endonucleases, are similar to 
apoptosis, often called programmed cell death 
(Eastman et al., 1990).  
Recent evidence has suggested a role for 
the p53 gene in response to DNA damage 
(Lane, 1992). Genetic alteration of p53 is one 
of the most frequently observed changes in 
human neoplasia and the p53 gene has been 
implicated both as a proto-oncogene and as a 
tumor suppressor gene. The level of p53 gene 
has been shown to be increased in cells after 
treatment with a variety of DNA damaging 
agents, including chemotherapeutic agents. In 
the case of ionizing radiation, p53 levels alter 
in temporal association with a G1 cell cycle 
arrest in cells with wild type p53; cells with 
mutant p53 do not arrest at G1 (Kastan et al., 
1991). It has been suggested that wild type 
p53 has a role in the inhibition of DNA 
synthesis following DNA damage, and 
alteration of p53 may cause a failure of this 
inhibition, an increased sensitivity to DNA 
damage and an increased mutation rate in the 
genome (Yarnold et al., 1993)  
It has been postulated that the drug 
sensitivity of certain tumor types may be due 
to deficiencies of DNA repair in these cells 
that acquired during development of the 
tumor. If defective DNA repair processes are 
involved in tumor development, identification 
of the particular defect in tumors and hence 
the DNA damage sensitivity could have 
important implications for the choice of 
chemotheraphy treatment agents (Yarnold et 
al., 1993).   
 
Conclusion    
The finding of amplifications and deletions of 
regions in these three human gliomas cell 
lines by CGH and FISH before and after 
treatment with SMDB-Cd has opened up a 
new window for identifying subtypes of 
gliomas and may enable the identification of 
rational theraphies that address the 
fundamental molecular defects. This will 
hopefully be pursued further by other 
researchers so as to confirm and expand these 
primary findings. 
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